Get started
Author

Чепоров Сергей Валентинович

Observed names: S Cheporov, S. Cheporov, S. V. Cheporov, S.V. Cheporov, S.  V. Cheporov, Sergey Cheporov, Sergey V. Cheporov
Observed institutions: Northwestern University, University of North Carolina at Chapel Hill, F. Hoffmann-La Roche AG, Universitat Autònoma de Barcelona, Nottingham University Hospitals NHS Trust, The University of Texas MD Anderson Cancer Center, Nizam's Institute of Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Yaroslavl State Medical Academy, Fudan University, Leningrad Regional Cancer Center, Marqués de Valdecilla University Hospital, City Clinical Oncology Center, Yaroslavl State Pedagogical University, Orenburg Regional Clinical Oncology Center, Instituto de Biomedicina de Sevilla, Chelyabinsk Regional Clinical Oncology Center, Hospital Universitario Virgen del Rocío, Abraxis (United States), Moscow City Oncology Hospital №62, Vall d'Hebron Institute of Oncology, Celgene (United States), Universidad de Sevilla
ORCID: 0000-0003-2776-4994
Observed ORCID: 0000-0003-2776-4994
OpenAlex ID: A5090599068
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
2022 · Ying Cheng, Liang Han, et al. · JAMA · 540
Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
2009 · William J. Gradishar, Dimitry Krasnojon, et al. · Journal of Clinical Oncology · 344
Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival
2012 · William J. Gradishar, Dimitry Krasnojon, et al. · Clinical Breast Cancer · 120
Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial
2013 · Josep Tabernero, Rocio Garcia-Carbonero, et al. · Clinical Cancer Research · 90
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
2010 · Mark A. Socinski, Georgiy M. Manikhas, et al. · Journal of Thoracic Oncology · 80
PDF
Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
2007 · W. Gradishar, D. Krasnojon, et al. · Journal of Clinical Oncology · 29
Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer
2011 · A.U. Buzdar, B. Xu, et al. · Annals of Oncology · 13
Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial.
2011 · W. J. Gradishar, D. Krasnojon, et al. · Journal of Clinical Oncology · 9
Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients
2010 · A.V. Muravyov, S.V. Cheporov, et al. · Clinical Hemorheology and Microcirculation · 8
Hemorheological changes in solid tumor patients after treatment with recombinant erythropoetin
2009 · A.V. Muravyov, S.V. Cheporov, et al. · Clinical Hemorheology and Microcirculation · 8
Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC)
2006 · M. J. Hawkins, M. Georgy, et al. · Journal of Clinical Oncology · 7
Alteration of red blood cell microrheology by anti-tumor chemotherapy drugs
2016 · I. A. Tikhomirova, A. V. Muravyov, et al. · Biochemistry (Moscow) Supplement Series A Membrane and Cell Biology · 6
Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)
2009 · R. Earhart, S. Cheporov, et al. · Journal of Clinical Oncology · 6
Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)
2008 · W. Gradishar, D. Krasnojon, et al. · European Journal of Cancer Supplements · 6
Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
2007 · M. J. Hawkins, G. Manikhas, et al. · Journal of Clinical Oncology · 5
Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)
2016 · M. Fedyanin, S. Tjulandin, et al. · Annals of Oncology · 4
PDF
First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)
2008 · D. A. Karlin, S. V. Cheporov, et al. · Journal of Clinical Oncology · 4
The choice of treatment for chemorefractory colon cancer
2023 · M.  S. Cheporova, S.  V. Cheporov, et al. · Malignant tumours · 2
PDF
Evaluation of Overall Survival Rate of Patients with Metastatic Colorectal Cancer Depending on Choice of Treatment, Location of Primary Focus and RAS Genes Mutation Status
2023 · Nikolay P. Shiryayev, Sergey V. Cheporov, et al. · I P Pavlov Russian Medical Biological Herald · 2
Pharmacotherapy regimens for patients with hormone-receptor positive (HR+), human epidermal growth factor 2 negative (HER2–) metastatic breast cancer in routine clinical practice (results of non-interventional retrospective study)
2023 · A. V. Sultanbaev, R. I. Fatyhov, et al. · Medical alphabet · 2
PDF
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
2020 · Mikhail Fedyanin, Alexey Tryakin, et al. · Journal of Clinical Oncology · 2
Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)
2016 · N. Tannir, T. Powles, et al. · Annals of Oncology · 2
PDF
5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial
2011 · W.J. Gradishar, D.A. Krasnojon, et al. · European Journal of Cancer · 2
A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer (HRPC)
2008 · H. B. Breitz, L. A. Roman, et al. · Journal of Clinical Oncology · 2
2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer
2007 · W.J. Gradishar, D. Krasnojon, et al. · European Journal of Cancer Supplements · 2
Works count: 53
Citation count: 1,299
H-index: 8
I10-index: 7
Year
Topic
Type